Abstract: Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R2 and R3 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R4 and R5 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R6 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R7 and R8 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R9 and R10 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R11 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.

Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.

Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each repres